Physician profile
Florence Barricelli
NPI 1861498875
$4,301.30
in general payments reported to CMS, 2019-2025
35 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $57.46 · 2021: $407 · 2022: $239 · 2023: $973 · 2024: $1,382 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,473.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $897.65 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $421.82 | 2022-2025 | Ubrelvy, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $358.38 | 2022-2025 | Airsupra, Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $349.60 | 2021-2024 | |
| Glaxosmithkline, LLC. | $304.09 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $208.39 | 2024-2025 | Repatha, Otezla, Repatha |
| Eisai INC. | $186.74 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.74 | 2021-2025 | Jardiance, Tradjenta, Ofev |
| Exact Sciences Corporation | $167.86 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $165.66 | 2021-2025 | |
| Boston Scientific Corporation | $124.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $110.71 | 2022-2024 | Xarelto |
| Astellas Pharma US INC | $101.98 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $73.01 | 2025 | Gemtesa |
| Daiichi Sankyo INC. | $66.85 | 2022-2024 | Injectafer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.90 | 2021-2025 | Zepbound, Mounjaro |
| Upsher-Smith Laboratories LLC | $56.52 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $56.23 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $44.87 | 2023-2024 | Nexletol |
| Inspire Medical Systems, INC. | $42.27 | 2025 | Inspire |
| Althera Pharmaceuticals LLC | $36.49 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.04 | 2024 | |
| Recordati_rare_diseases_inc. | $30.80 | 2025 | Isturisa |
| Electromed, INC. | $28.02 | 2025 | Smartvest |
| Shield Therapeutics INC | $23.70 | 2023 | Accrufer |
| Abbott Laboratories | $21.88 | 2025 | Cardiomems |
| Evofem Biosciences, INC. | $20.40 | 2020 | |
| Almatica Pharma LLC | $19.37 | 2024 | Loreev Xr |
| Axsome Therapeutics, INC. | $18.23 | 2025 | Auvelity |
| Amneal Pharmaceuticals LLC | $16.73 | 2025 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $16.10 | 2023 | Seglentis |
| Philips North America LLC | $15.25 | 2021 | |
| Vistapharm, INC. | $14.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2021 | |
| Merck Sharp & Dohme LLC | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florence Barricelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.